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ABSTRACT
Object The aim of this study is to demonstrate the
differences between the new Low-proﬁle Visualized
Intraluminal Support (LVIS Blue) stenting device and the
Flow Redirection Endoluminal Device (FRED) using a
series of bench-top evaluations and optical coherence
tomography (OCT) images in a cadaveric preparation of
the basilar artery.
Methods The ﬁrst part of the evaluation was bench-
top microscopic documentation of metal coverage for
LVIS Blue and FRED stents. OCT images of the cerebral
vessels and deployed stents were acquired using OCT
intravascular imaging. The stents were deployed from the
left posterior cerebral artery to the basilar artery in a
fresh frozen cadaver. Wall apposition and the
relationship to jailed perforators were evaluated.
Results The metal coverage along the inner curves of
the LVIS Blue stent was similar to that along the outer
curves of the FRED stent. The LVIS Blue stent cell size
was compatible for crossing with the tested
microcatheters after deployment of the stent. The LVIS
Blue stent showed better wall apposition and less
coverage of the perforator than the FRED stent in the
cadaver experiment.
Conclusions LVIS Blue has a good crossing proﬁle for
microcatheters, better wall apposition, and less
perforator coverage than FRED. These are desirable
features in territories with high densities of perforators
such as the posterior circulation.
INTRODUCTION
Endovascular treatment of complex intracranial
aneurysms requires an extensive armamentarium of
devices and new strategies. Certain types of cere-
bral aneurysms, particularly giant partially throm-
bosed and fusiform aneurysms, are considered to
be the most challenging for treatment.1 2 Self-
expandable intracranial stents have been increasingly
used to treat these aneurysms. However, because of
the low metal-to-artery ratio, the recurrence rate
remains high. Flow diverters (FDs) have increased
the rate of durable occlusion of wide-neck cerebral
aneurysms. Holobasilar fusiform aneurysms are still
a signiﬁcant challenge due to the number of possible
treatment complications and morbid natural history.
The use of FDs on the posterior circulation has
been associated with thromboembolic complications
related to perforators.3 4
The development of a device to cover the gap
between the ﬁrst generation of self-expanding intra-
cranial stents and FDs is very appealing. The
Low-proﬁle Visualized Intraluminal Support device
Blue (LVIS Blue; MicroVention, Tustin, California,
USA) is a braided stent and provides a higher
degree of metal coverage (approximately 28%)
than the ﬁrst generation of self-expanding devices.
The coverage of this stent is higher than that of the
previous LVIS stent (approximately 23%) but lower
than that of FDs (30–35%).5
We studied the performance of the new LVIS in
different bench and cadaver models and compared
it with that of a ﬂow diverter Flow Redirection
Endoluminal Device (FRED; MicroVention). We
used a microscope in bench-top models and optical
coherence tomography (OCT) imaging in the
basilar artery (BA) of a human fresh frozen cadaver.
METHODS
LVIS Blue
The LVIS Blue device is a self-expanding nickel
titanium (nitinol), 16 single-wire braided, compli-
ant, closed-cell design stent. This stent, which is
compatible with a 0.021 inch microcatheter, has a
cell size of 0.8 mm and is recommended for parent
vessels with diameters of 2.5–4.5 mm. It has four
radiopaque tantalum markers on the proximal/
distal ends with two helical strands within the body
of the stent. The LVIS device can be recaptured to
up to approximately 75% deployment of its total
length.
Flow Redirection Endoluminal Device (FRED)
The FRED stent is a self-expanding nickel titanium,
single-wire braided, compliant, closed-cell paired-
stent design composed of a low-porosity inner
mesh of higher pore attenuation (48 nitinol wires)
and an outer stent with high porosity (16 nitinol
wires) designed mainly for the aneurysm neck. This
stent, which is compatible with a 0.027 inch micro-
catheter, is recommended for a parent vessel size of
2.5–5.5 mm. It has four radiopaque markers on
each end of the outer stent and two interwoven
helical marker strands that attach the inner and
outer stents, improving the visibility over its full
length of dual-layer coverage. This FRED stent can
be resheathed for up to 50% deployment of its
total length.
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Bench-top experiment
Bench-top experiments were performed to evaluate changes of
neck coverage surface area (%). We made a fusiform aneurysm
using clear silicone tubes slit down the middle, with an inner
diameter of 3 mm. The LVIS Blue stent (3.5×22 mm and
4.5×23 mm) and FRED stent (3.5×22 mm and 4.0×22 mm)
were deployed twice between the proximal and distal silicone
tube, which was empty in the middle portion. These models
were ﬁxed in a straight and 180° curved fashion and photo-
graphed under a microscope.
The neck coverage surface areas are shown in ﬁgure 1. The
mean neck coverage surface area (%) was calculated as
[1−(Z×L)/(X×Y)]×100, where X and Y are each side of an
imaginary rectangle on the stent, Z is the width of the struts,
and L is the length of total struts in the rectangle. L was calcu-
lated as follows: L (mm)=total length of struts−Z2×N, where
N is the number of intersections by the two struts. In the
straight model, we measured surface coverage at the center. The
three types of metal coverage were measured in the straight
model because three different zones were found in the square
on the stent in ﬁgure 1 left. The three zones were deﬁned as the
middle of the aneurysm neck (mid-zone), the transition between
the parent artery and the neck (transition zone), and the zone
between the mid-zone and the transition zone (high-density
zone). Both meshes in the FRED stent were calculated. In the
straight model, the lengths X and Y were 1.20 mm and
1.85 mm, respectively. In the curved model, the outside and
inside areas in the center of the curvature were measured. The
lengths X and Y were each 1.25 mm.
To prove the feasibility for additional coil insertion after
deployment of the device, we evaluated the possibility of stent
cell penetration for the devices in the 180° curved model using
Echelon-10, Marathon (ev3, Plymouth, Minnesota, USA), and
Headway Duo microcatheters (MicroVention).
OCT imaging in the fresh frozen cadaver
This study was performed with a fresh frozen human cadaver.
Brain and intracranial vessels were removed from the human
cadaver. A 6 and 5 French short sheath were inserted via the left
and right vertebral arteries (VAs) and ﬁxed, respectively. OCT
images were obtained after the Dragonﬂy Optis intravascular
Imaging Catheter (Lightlab Imaging, St Jude Medical, St Paul,
Minnesota, USA) was advanced into the left posterior cerebral
artery (PCA) through the sheath in the left VA along a micro-
wire monorail system. The LVIS Blue stent (4.5×32 mm) and
FRED stent (4.0×32 mm) were selected because the diameter
of the BA was 3.57 mm. The LVIS Blue stent was deployed
twice from the left PCA to the BA. OCT images were obtained
after deployment of the stent. The same procedure was per-
formed for the FRED stent after the LVIS Blue stent was
removed. To obtain clear images, residual cadaveric blood pro-
ducts were ﬂushed with contrast injection through the sheath in
the right VA. Ofﬂine OCT analysis was performed with Lightlab
Imaging software.
RESULTS
The mean metal coverages of LVIS Blue and FRED are shown in
ﬁgure 1. The metal coverages of the LVIS Blue stent in the
mid-zone, high-density zone and transition zone were 21.3%,
27.3% and 20.6%, respectively. The effect of oversizing add-
itionally led to a change in the metal coverages (4.2%, 7.2%
and −2.2%). On the other hand, no difference in the metal cov-
erages of the FRED stent was seen among the positions (38.8%,
39.2% and 37.5%). Furthermore, there was hardly any differ-
ence in metal coverages for the oversized stent (39.5%, 41.5%
and 34.6%). The neck coverage for the high-density zone in the
4.5 mm LVIS Blue stent was comparable to that of the FRED
stent. In addition, the inner neck coverage of the LVIS Blue
stent was similar to the outer neck coverage of the FRED stent
in the 180° curved model.
A trans-cell approach after deployment of the stent was per-
formed using Echelon-10, Marathon and Headway Duo micro-
catheters. The trans-cell approach was shown to be feasible after
deployment of the LVIS Blue stent (ﬁgure 2). It was impossible
to penetrate the stent strut of FRED. This result was consistent
with the result of the smaller cell size in the FRED stent than
the LVIS Blue stent (ﬁgure 1).
Figure 3 shows OCT images after each deployment of the
LVIS Blue 4.5 mm stent (upper) and the FRED 4.0 mm stent
(lower) in the BA, which had a mean diameter of 3.57 mm. The
distance between the oriﬁce of the perforator and the stent strut
was 0.10 mm with the LVIS Blue stent and 0.21 mm with the
Figure 1 Photographs by microscope showing straight (left) and 180° curved models (right) of a fusiform aneurysm in a 3 mm diameter vessel in
which the new Low-proﬁle Visualized Intraluminal Support device (LVIS Blue) (3.5 mm and 4.5 mm) and the Flow Redirection Endoluminal Device
(FRED) (3.5 mm and 4.0 mm) were deployed. Left: the neck coverages for each stent in the three zones (mid-zone; M: high-density zone; H:
Transition zone; T) are shown in a straight model. Right: the neck coverages for each stent in the outer and inner curves are shown in a 180° curved
model.
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FRED stent. In whole vessel image, the LVIS Blue stent showed
better wall apposition than the FRED stent. The oriﬁce of the
perforator was covered by one stent strut with the LVIS Blue
stent compared to two with the FRED stent.
DISCUSSION
The most important ﬁnding in this study is that the LVIS Blue
stent demonstrated feasibility for the trans-cell approach and
better wall apposition and less perforator coverage than the
FRED stent. In addition, this stent showed that inner metal
coverage in the curved model was comparable to metal coverage
of FDs. Therefore, this study suggests the possibility that this
stent has an advantage over FDs and previous intracranial
stents.
The new LVIS Blue stent has a smaller angle between the
wires of the mesh. This modiﬁcation resulted in better wall
apposition and denser mesh compared with the ﬁrst-generation
LVIS. The braided morphology showed better conformability,
apposition to the vessel wall, and stability.6 This design allowed
the LVIS Blue stent to be delivered through lower proﬁle micro-
catheters (0.021 inch) than the FRED stent (0.027 inch). The
lower proﬁle means that it is easier to deploy the stent into
Figure 2 Photographs showing the possibility of protrusion through the stent strut using three types of microcatheter. The Flow Redirection
Endoluminal Device (FRED) shows the impossibility of protrusion. The white circles show the tips of the microcatheters.
Figure 3 Photographs showing
optical coherence tomography (OCT)
images after deployment of the new
Low-proﬁle Visualized Intraluminal
Support device (LVIS Blue) (top) and
the Flow Redirection Endoluminal
Device (FRED) (bottom) in the same
vessel. Defects of the vessel wall
indicated by white squares show a
perforator. The oriﬁce of the perforator
and the stent strut are seen in the
magniﬁed views. The LVIS Blue stent
demonstrates better wall apposition
and less perforator coverage than the
FRED stent.
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more distal vessels and to use an adjunctive method. In addition,
as the cell size of the braided stent is more easily changed than
with other stents, the LVIS Blue stent allows crossing with
microcatheters through the stent cells to place coils in aneur-
ysms (ﬁgure 2). On the other hand, it is impossible to penetrate
the stent strut of the FRED device because of the small cell size.
After recanalization of an aneurysm treated with the LVIS Blue
stent is recognized, retreatment by a trans-cell approach is
possible.
The neck coverage of FDs was reported to be 30–35%.5 The
porosity of the stent induces the possibility of ﬂow stasis in the
aneurysm due to rapid thrombosis.7 Generally, pore number can
play an important role in thrombosis. Our results showed that
the FRED stent had a high pore density while the LVIS Blue
stent had a much lower pore density. Furthermore, FDs may
provide scaffolding for endothelialization and vessel wall
healing. For these reasons, FDs demonstrate a higher occlusion
rate for intracranial aneurysms than most stents. On the other
hand, the neck coverage for an intracranial stent was reported
to be 10% in Neuroform and 9% in Enterprise.8 The main
purpose of the intracranial stent is to keep coils in the aneurysm,
and especially to insert ﬁnishing coils so that a higher occlusion
rate can be achieved. Additionally, these intracranial stents are
feasible for retreatment via a trans-cell approach because of low
neck coverage. In our results, the LVIS Blue stent showed higher
neck coverage than previous intracranial stents. The inner neck
coverage with the LVIS Blue stent in the curved model was com-
parable to 30–35% of FDs reported previously (ﬁgure 1,
right).5 A high aneurysm occlusion rate, similar to that of FDs,
might be particularly expected for an aneurysm in the inner
curve of a vessel. However, we should take into consideration
the impossibility of the trans-cell approach and the concern for
the ischemic complications of a perforator originating from the
inner curve.
In the case of an oversized LVIS Blue stent, the transition
zone showed lower neck coverage than the proper-sized stent in
ﬁgure 1, left (18.4% vs 20.6%). On the other hand, a greater
neck coverage rate was shown in the high-density zone of a
4.5 mm LVIS Blue stent than a 3.5 mm stent (34.5% vs 27.3%).
Shapiro et al9 reported that the funnel-shaped transitional zone
in the Pipeline Embolization device (PED; Medtronic) was
dependent on the degree of mismatch between the device diam-
eter and the diameter of the recipient artery. In addition, they
also reported that PEDs deployed in larger tube diameters than
the nominal device diameter showed more metal coverage.
Taking this into account, these results are consistent with our
results that metal coverage in the transition zone of the 4.5 mm
LVIS Blue stent is less than the 3.5 mm LVIS Blue stent but is
more in the mid-zone and high-density zone. In the straight
model, the neck coverage of the 4.5 mm LVIS Blue stent was
comparable to FDs in the high-density zone. As the high-density
zone is consistent with the outﬂow of an aneurysm, this result
might induce more ﬂow stasis so that the LVIS Blue stent could
show a higher aneurysm occlusion rate. Meanwhile, these
results suggest that the stent strut in the 4.5 mm stent was more
compressed in the high-density zone such that stent migration
may occur if the landing zone is short. Although the difference
in neck coverage between the 3.5 mm and 4.0 mm FRED stent
was smaller, the same tendency was shown. These observations
are in excellent agreement with the results published by Shapiro
et al.5 9
In our OCT experiment, the LVIS Blue stent showed better
wall apposition than the FRED stent (ﬁgure 3). In addition, the
LVIS Blue stent expanded further outward than the FRED stent
(ﬁgure 1). These results conﬁrm that the LVIS Blue stent had
greater apposition to the vessel wall, as described above. In pre-
vious reports, insufﬁcient opening of the FD was reported to
occur in up to 10% of cases.10–12 Additionally, Heller et al13
reported that incomplete stent apposition of the Enterprise stent
was associated with periprocedural ipsilateral thromboembolic
complications. Moreover, in 5 of 29 patients (17%), in-stent per-
cutaneous transluminal angioplasty (PTA) was required because
the risk of thrombus formation and subsequent parent artery
occlusion is high if wall apposition is not adequate.3 14 15 Use of
the LVIS Blue stent might reduce the thromboembolic complica-
tions due to malposition and complications related to PTA.
There are some reports on perforator infarction after deploy-
ment of FDs. One of 29 patients showed delayed perforator
stroke by diffusion-weighted imaging despite sufﬁciently effect-
ive antiplatelet therapy according to platelet function tests.3
Phillips et al4 reported that the permanent neurologic complica-
tion rate was 9.4%; in particular, perforator territory infarctions
occurred in 14% of patients with BA aneurysms. Brinjikji et al16
reported that perforator infarction was 3%, but signiﬁcantly
higher odds were found among patients with posterior circula-
tion aneurysms. Additionally, Kallmes et al17 reported that
ischemic stroke rates were 4.7%, and even higher in patients
with posterior circulation aneurysms (7.3%). The treatment for
a fusiform aneurysm in the posterior circulation is still challen-
ging because there are many perforators in the BA. In our OCT
experiment, the LVIS Blue stent showed less perforator coverage
than the FRED stent (ﬁgure 3). This result suggests that the
LVIS Blue stent could reduce ischemic complications related to
perforators.
As a result, better wall apposition and less perforator coverage
in the LVIS Blue stent might reduce ischemic complications. In
addition, neck coverage comparable to FDs might induce a
higher rate of aneurysmal occlusion than previous intracranial
stents. It is possible that this stent offers a ray of hope for fusi-
form aneurysms in the posterior circulation and may be a treat-
ment option in the near future. A clinical trial is needed to prove
its feasibility in the treatment of posterior fusiform aneurysms.
This main limitation is that this is not an in vivo experiment,
so clinical practice might show different results. In the curved
model we focused the line of sight of the camera around the
center of the stent, which might be less accurate about the
surface coverage of the outer and inner curve (ﬁgure 1).
Determining perforator coverage in the OCTexperiment is chal-
lenging as the two devices have different wire diameters.
Counting the number of struts near the perforator oriﬁce could
provide very limited information for comparing perforator
occlusion. In addition, there is no statistical comparison in this
paper. More models and devices should be examined by way of
comparison.
CONCLUSIONS
Retreatment after deployment of the LVIS Blue stent was pos-
sible via the trans-cell approach. The LVIS Blue stent demon-
strated the possibility of better wall apposition and less
perforator coverage than the FRED stent in our cadaver experi-
ment. In particular, the inner metal coverage in the curved
model was comparable to metal coverage of FDs. The LVIS Blue
stent is expected to show a higher aneurysm occlusion rate than
an intracranial stent and fewer perforator-related ischemic com-
plications than FDs. This stent might be a good option for the
treatment of fusiform aneurysms in the posterior circulation.
Clinical studies using this stent are needed.
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